Skip Navigation

European Heart Journal 2000 21(18):1547-1554; doi:10.1053/euhj.2000.2125
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Friberg, L
Right arrow Articles by Ahnve, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Friberg, L
Right arrow Articles by Ahnve, S
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Growth hormone and insulin-like growth factor-1 in acute myocardial infarction

L Friberga, S Wernerb, G Eggertsenc and S Ahnved,f1

a Department of Cardiology, Karolinska Institutet at Huddinge Hospital, Stockholm, Sweden
b Centre of Metabolism and Endocrinology, Karolinska Institutet at Huddinge Hospital, Stockholm, Sweden
c Department of Clinical Chemistry, Karolinska Institutet at Huddinge Hospital, Stockholm, Sweden
d Department of Cardiology and Division of Preventive Medicine, Karolinska Institutet at Huddinge Hospital, Stockholm, Sweden

revised September 28, 1999; accepted January 6, 2000

Abstract

Background Growth hormone therapy after myocardial infarction improves cardiac function and survival in animals. Beneficial effects in humans are reported from studies where patients with idiopathic dilated cardiomyopathy were treated with growth hormone. We have studied the role of the endogenous growth hormone system in myocardial infarction.

Methods and Results Fifty-two consecutive patients with acute myocardial infarction were studied during the first 5 days and at follow-up 6 and 12 weeks later. The time from chest pain onset was used in the analyses. The mean growth hormone level within the first 6h was nearly three times higher (1·1±0·2µg.l–1) than on the third day (0·4±0·05µg.l–1, P<0·0002). It remained higher in patients with higher levels of cardiac enzymes, impaired left ventricular function and intense inflammatory response. Insulin-like growth factor-1 (IGF-1) declined slowly but remained within the normal range throughout the whole study period. Patients who died within 2 years had higher levels of growth hormone and lower levels of IGF-1, indicating growth hormone resistance. Endogenous levels of growth hormone or IGF-1 did not correlate with improvement in left ventricular function at 6 weeks.

Conclusions The growth hormone axis is stimulated early in acute myocardial infarction, particularly in patients with more severe cardiac damage. Whether treatment with growth hormone can be beneficial for patients with heart failure after myocardial infarction remains to be investigated.

Key Words: Growth hormone, insulin-like growth factor-1, heart failure, acute myocardial infarction, C-reactive protein

f1 Correspondence: Staffan Ahnve, MD, PhD, FACP, FACC, FESC, Department of Cardiology and Division of Preventive Medicine, Karolinska Institutet at Huddinge University Hospital, S-141 86 Stockholm, Sweden.

References

  1. Rosen T, Bengtsson B. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990;336:285–288[CrossRef][ISI][Medline]
  2. Bengtsson B, Lombardi G. Increased atherosclerosis in hypopituitarism: can it be explained? (Workshop report). Endocrinol Metab. 1996;3:111–113
  3. Markussis V, Beshyah SA, Fisher C, Sharp P, Nicolaides AN, Johnston DG. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet. 1992;340:1188–1192[CrossRef][ISI][Medline]
  4. Caidahl K, Johannsson G, Bengtsson B. Cardiac consequences of growth hormone deficiency and effects of growth hormone replacement therapy. Endocrinol Metab. 1997;4:21–26
  5. Cuneo RC, Salomon F, Watts GF, Hesp R, Sönksen PH. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism. 1993;42:1519–1523[CrossRef][ISI][Medline]
  6. Saccá L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev. 1994;15:555–573[Abstract]
  7. Ohtsuka H, Komiya I, Aizawa T, Yamada T. Hypertension in acromegaly: hereditary hypertensive factor produces hypertension by enhancing IGF-1 production. Endocr J. 1995;42:781–787[ISI][Medline]
  8. Fazio S, Cittadini A, Biondi B, Riccio G, Sabatini D, Saccá L. Heart failure caused by dilated cardiomyopathy: rationale for treatment with growth hormone. Endocr Metab. 1997;4:33–36
  9. Cuocolo A, Nicolai E, Colao S. Improved left ventricular function after growth hormone replacement in patients with hypopituitarism: assessment with radionucleide angiography. Eur J Nucl Med. 1996;23:390–394[CrossRef][ISI][Medline]
  10. Johannsson G, Bengtsson B, Andersson B, Isgaard J, Caidahl K. Longterm cardiovascular effects of growth hormone treatment in GH-deficient adults. Preliminary data in a small group of patients. Clin Endocrinol. 1996;45:305–314[CrossRef][Medline]
  11. Amato G, Carella C, Fazio S. Body composition, bone metabolism and heart structure and function in growth hormone (GH)-deficient adult before and after GH replacement therapy at low doses. J Clin Endocrinol Metab. 1993;77:1671–1676[Abstract]
  12. Cittadini A, Cuocolo A, Merola B. Impaired cardiac performance in GH deficient adults and its improvement after GH replacement. Am J Physiol. 1994;267:E219–225
  13. Merola B, Cittadini A, Colao A. Chronic treatment with octreotide improves cardiac abnormalities in patients with acromegaly. J Clin Endocrinol Metab. 1993;77:790–793[Abstract]
  14. Frustaci A, Perrone GA, Gentiloni N, Russo M. Reversible dilated cardiomyopathy due to growth hormone deficiency. Am J Clin Pathol. 1992;97:503–511[ISI][Medline]
  15. Fazio S, Biondi B, Sabatini D. Long-term growth hormone deficiency and its reversibility with specific replacement therapy. J Clin Endocrinol Metab. 1996;81:887–890[CrossRef][ISI][Medline]
  16. Anand I, Ferrari R, Kalra G, Wahi P, Poole-Wilson P, Harris P. Edema of cardiac origin: studies of body water and sodium, renal function, hemodynamic indexes and plasma hormones in untreated congestive cardiac failure. Circulation. 1989;80:299–305[Abstract/Free Full Text]
  17. Mangieri E, Croce CT, Tanzilli G. Growth hormone and insulin-like growth factor 1 in normopituitaric patients with various degrees of heart failure. Ann NY Acad Sci. 1995;752:429–431[ISI][Medline]
  18. Ketelslegers JM, Beauloye V, Defalque D. Starvation or sepsis as causes of growth hormone insensitivity. Endocrinol Metab. 1997;4:71–80
  19. Ross RJM, Chew SL. Acquired Growth hormone resistance. Eur J Endocrinol. 1995;132:655–660[ISI][Medline]
  20. Finidori J. Growth hormone receptor signalling and potential interactions with other cytokine receptors. Endocrinol Metab. 1997;4:51–55
  21. Fazio S, Sabatini D, Capaldo B. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 1996;334:809–814[Abstract/Free Full Text]
  22. Cittadini A, Grossman JD, Napoli R. Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J Am Coll Cardiol. 1997;29:1109–1116[Abstract]
  23. Yang R, Bunting S, Gilett N, Clark R, Jin H. Growth hormone improves cardiac performance in experimental heart failure. Circulation. 1995;92:262–267[Abstract/Free Full Text]
  24. Duerr R, Huang S, Miraliakbar H, Clark R, Chien K, Ross J Jr. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest. 1995;95:619–627[ISI][Medline]
  25. Jin H, Yang R, Gillett N, Clark RG, Ko A, Paoni NF. Beneficial effects of growth hormone and insulin-like growth factor-1 in experimental heart failure in rats treated with chronic ACE-inhibition. J Cardiovasc Pharmacol. 1995;26:420–425[ISI][Medline]
  26. Ross J Jr, Hongo M. The role of hypertrophy and growth factors in heart failure. J Card Fail. 1996;2:S121–128[CrossRef][Medline]
  27. Yang R, Bunting S, Gillett N, Clark RG, Jin H. Effects of growth hormone in rats with postinfarction left ventricular dysfunction. Cardiovasc Drugs Ther. 1995;9:121–131
  28. Isgaard J, Kujacic V, Jennische E. Growth hormone improves cardiac function in rats with experimental myocardial infarction. Eur J Clin Invest. 1997;27:517–525[CrossRef][ISI][Medline]
  29. Duerr RL, McKirnan MD, Gim RD, Clark RG, Chien KR, Ross J Jr. Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat. Circulation. 1996;93:2188–2196[Abstract/Free Full Text]
  30. Hartman M. Physiological regulators of growth hormone secretion. Juul A, Jørgenssen J. Growth hormone in adults. Cambridge: Cambridge University Press; 1995. p. 5–35
  31. Laursen T. Pharmacological aspects of growth hormone replacement therapy. Juul A, Jørgenssen J. Growth hormone in adults. Cambridge: Cambridge University Press; 1996. p. 122–144
  32. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy. Am J Cardiol. 1976;1:7–11
  33. Pai R, Bodenheimer M, Pai S, Koss J, Adamik R. Usefulness of systolic excursion of the mitral annulus as an index of left ventricular systolic function. Am J Cardiol. 1991;67:222–224[CrossRef][ISI][Medline]
  34. Hilding A, Brismar K, Degerblad M, Thorén M, Hall K. Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy patients. J Clin Endocrinol Metab. 1995;80:2646–2652[Abstract]
  35. Blum WF. Insulin-like growth factors and IGF-binding proteins: their use for diagnosis of growth hormone deficiency. Juul A, Jørgenssen J. Growth hormone in adults. Cambridge: Cambridge University Press; 1996. p. 48–74
  36. Tyrell B, Findling J, Aron D, Greenspan FS, Baxter JD. Hypothalamus and pituitary. Greenspan FS, Baxter JD. Basic and Clinical Endocrinology. London: Prentice-Hall International, Appleton & Lange; 1994. p. 75–77
  37. Tönshoff B, Mehls O. Interactions between glucocorticoids and the somatotrophic axis (Review). Acta Paediatr. 1996;85:72–75

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
S. Gavi, D. Yin, E. Shumay, H.-y. Wang, and C. C. Malbon
Insulin-Like Growth Factor-I Provokes Functional Antagonism and Internalization of {beta}1-Adrenergic Receptors
Endocrinology, June 1, 2007; 148(6): 2653 - 2662.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
M. Yazdanpanah, F. A Sayed-Tabatabaei, J. A M J L Janssen, I. Rietveld, A. Hofman, T. Stijnen, H. A P Pols, S. W J Lamberts, J. C M Witteman, and C. M van Duijn
IGF-I gene promoter polymorphism is a predictor of survival after myocardial infarction in patients with type 2 diabetes.
Eur. J. Endocrinol., November 1, 2006; 155(5): 751 - 756.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
G. Sesti, A. Sciacqua, M. Cardellini, M. A. Marini, R. Maio, M. Vatrano, E. Succurro, R. Lauro, M. Federici, and F. Perticone
Plasma Concentration of IGF-I Is Independently Associated With Insulin Sensitivity in Subjects With Different Degrees of Glucose Tolerance
Diabetes Care, January 1, 2005; 28(1): 120 - 125.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Napoli, V. Guardasole, V. Angelini, F. D'Amico, E. Zarra, M. Matarazzo, and L. Sacca
Acute Effects of Growth Hormone on Vascular Function in Human Subjects
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2817 - 2820.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
E. Conti, D. Pitocco, E. Capoluongo, C. Zuppi, G. Ghirlanda, F. Crea, and F. Andreotti
IGF-1 and Macrovascular Complications of Diabetes: Alternative interpretations of recently published data
Diabetes Care, May 1, 2003; 26(5): 1653 - 1654.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. Conti, F. Andreotti, A. Sciahbasi, P. Riccardi, G. Marra, E. Menini, G. Ghirlanda, and A. Maseri
Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction
J. Am. Coll. Cardiol., July 1, 2001; 38(1): 26 - 32.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
K.C. Wollert and H. Drexler
Growth hormone and insulin-like growth factor--friends of the infarcted heart?
Eur. Heart J., September 2, 2000; 21(18): 1499 - 1501.
[PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Friberg, L
Right arrow Articles by Ahnve, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Friberg, L
Right arrow Articles by Ahnve, S
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?